Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort
Open Access
- 26 November 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 62 (5), 561-567
- https://doi.org/10.1093/cid/civ973
Abstract
Background. With the approval of direct-acting antivirals (DAAs), the management of drug–drug interactions (DDIs) has become an important challenge while treating individuals with hepatitis C. To date, the potential of causing DDIs for the recently approved DAAs has not been systematically investigated. We aimed to assess the clinical significance of DDI between the regular outpatient medications and DAA therapies in a large real-world cohort. Methods. Overall, 261 hepatitis C virus monoinfected patients who were selected for DAA therapy at 2 intervals between 2011 and 2014 were asked about their regular outpatient medications. The potential for DDIs between all these drugs and sofosbuvir/ribavirin, ledipasvir/sofosbuvir, sofosbuvir/daclatasvir, sofosbuvir/simeprevir, ombitasvir/paritaprevir/ritonavir ± dasabuvir as well as boceprevir and telaprevir triple therapy was assessed using www.hep-druginteractions.org and the relevant prescribing information. Results. The 261 patients took a median number of 2 drugs (range 0–15); 20% of patients did not take any medication. Sofosbuvir/ribavirin had the lowest risk to cause a potentially significant DDI (9.6%). In contrast, for ombitasvir/paritaprevir/ritonavir ± dasabuvir potentially significant DDIs could be expected in 66.3% of the patients. Significant DDIs for sofosbuvir/simeprevir would be expected in 31.4%, for sofosbuvir/daclatasvir in 36.8%, and for sofosbuvir/ledipasvir in 40.2%. Proton pump inhibitors, thyroid hormones, and dihydropyridine derivatives were frequently used and presented a risk of interacting with the antiviral regimen. Conclusions. A significant number of patients are at risk for DDIs if treated with the recently approved DAA regimens. A careful evaluation of potential DDI is essential to prevent adverse effects or unnecessary risk of treatment failure.Funding Information
- Integrated Research and Treatment Center Transplantation (IFB-Tx)
This publication has 21 references indexed in Scilit:
- Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidityBMJ, 2015
- Hepatitis CThe Lancet, 2015
- Eligibility and safety of the first interferon‐free therapy against hepatitis C in a real‐world settingLiver International, 2014
- New Hepatitis C Therapies: The Toolbox, Strategies, and ChallengesGastroenterology, 2014
- The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis CAlimentary Pharmacology & Therapeutics, 2013
- Drug–drug interactions during antiviral therapy for chronic hepatitis CNature Reviews Gastroenterology & Hepatology, 2013
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890Journal of Hepatology, 2013
- Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World SettingPLOS ONE, 2013
- Clinical management of drug–drug interactions in HCV therapy: Challenges and solutionsJournal of Hepatology, 2012
- New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye: Table 1Gut, 2012